Upregulation of SIRT1 and FOXO3a Contributes to The Protective Role of Estrogen on HPH in Rats

Li Wang  
The Second Hospital of Hebei Medical University  

Yadong Yuan  (✉ yyd1108@126.com )  
The Second Hospital of Hebei Medical University  

https://orcid.org/0000-0002-6634-387X

Xiaowei Gong  
The Second Hospital of Hebei Medical University

Jianjun Mao  
The Second Hospital of Hebei Medical University

Research article

Keywords: pulmonary hypertension, hypoxia, pulmonary artery smooth muscle cells, estrogen, SIRT1, FOXO3a

DOI: https://doi.org/10.21203/rs.3.rs-62907/v1

License: ☕️ ☐ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** SIRT1 has anti-proliferation effects on cells through regulating the expression and activity of FOXOs. Estrogen (E2) has protective effects against hypoxic pulmonary hypertension (HPH), but the involvement of SIRT1 and FOXOs in the proliferation of pulmonary artery smooth muscle cells (PASMCs) and contribution to the effects of E2 on HPH are poorly understood. To use E2 to explore the roles of SIRT1 and FOXO3a in the pathogenesis and progression of HPH and pulmonary vascular remodeling (PVR) in vivo and in vitro.

**Methods:** Female Sprague-Dawley rats with bilateral ovariectomy were randomized to normoxia, normoxia+E2, hypoxia, and hypoxia+E2. Serum E2 levels, hemodynamic, and pulmonary vascular pathomorphology were assessed. The anti-proliferation effect of E2 was determined in human PASMCs under hypoxia/normoxia. Immunohistochemistry, western blotting, and real-time PCR were used to assess SIRT1, FOXO3a, and PCNA in rat pulmonary artery and hPASMCs. SIRT1 activity was assayed.

**Results:** Hypoxia increased mean pulmonary artery pressure (mPAP), medial width of pulmonary arterioles, right ventricular hypertrophy index (RVHI), decreased expression SIRT1 and FOXO3a and increased PCNA expression in rats; E2 alleviated these changes. In vitro, E2 significantly inhibited hypoxia-induced hPASMCs proliferation, associated with improvements in SIRT1 and FOXO3a expression, consistent with the in vivo results. SIRT1 inhibition attenuated the effects of E2 on hPASMCs proliferation and the expression of FOXO3a. A SIRT1 activator mimicked the effects of E2 on hPASMCs proliferation and the expression of FOXO3a.

**Conclusions:** Upregulation of SIRT1 and FOXO3a contributes to the protective role of estrogen on HPH in rats, as supported by in vitro results using hPASMCs.

**Background**

Hypoxia-induced pulmonary hypertension (HPH) is one of the subtypes of pulmonary hypertension (PH) (1). HPH usually results from chronic hypoxia such as lung diseases-related hypoxia and chronic exposure to high altitude. In addition to hypoxia-induced pulmonary vasoconstriction, proliferation of pulmonary arterial smooth muscle cells (PASMCs) and pulmonary vascular remodeling (PVR) are central to the pathogenesis of HPH (2). Hypoxia-induced PVR can result in progressive increase of pulmonary vascular resistance, increased afterload of right ventricle (RV), and ultimately right heart failure (3).

A previous study by our group showed that ovariectomy exacerbates HPH in rats, whereas E2 replacement in ovariectomized animals attenuates the disease (4). It suggests that E2 exerts protective effects in HPH (5). The protective effects of E2 involve increased prostacyclin release and production of nitric oxide (6, 7), inhibition of endothelin-1 expression (8), and downregulation of angiotensin converting enzyme and angiotensin type 1 receptor (9), all leading to vasodilatation. In addition, E2 markedly alleviates hypoxia-induced PVR and proliferation of PASMCs (10). Moreover, E2 possesses anti-
proliferation effects in other proliferative vascular diseases (11). Nevertheless, the exact mechanisms underlying these effects of E2 are not fully understood.

SIRT1 is a highly conserved nicotinamide adenine dinucleotide (NAD)$^+$-dependent deacetylase, and regulates DNA damage repair, oxidative stress, cell senescence, apoptosis, and proliferation via its ability to deacetylate a variety of substrates such as transcription factors, coregulators, and histones (12). SIRT1 is highly expressed in the vasculature and plays a critical role in the development of many vascular diseases including PH (13). Decreased SIRT1 expression may contribute to PVR associated with PH and up-regulated SIRT1 mediates the inhibition on MCT-induced rat PVR and proliferation of PVSMCs (14).

FOXO3a, an isoform of the Forkhead box “O” (FOXO) transcription factors, plays an important role in regulating diverse cellular processes such as proliferation, differentiation, and cell cycle control (15, 16). FOXO3a is closely related to hypoxia and oxidation (17) and FOXOs are associated with PH (18). SIRT1 can deacetylate FOXO3a, controlling its activity or expression, and regulates FOXO-dependent gene transcription (19, 20).

We hypothesized that E2 inhibits the abnormal proliferation of PASMCs via the SIRT1/FOXO3a pathway and contributes to attenuating PVR and alleviating HPH. Therefore, the aim of the present study was to use E2 to explore the roles of SIRT1 and its target FOXO3a in the pathogenesis and progression of HPH and PVR in vivo. Furthermore, we verified the effects of SIRT1 and FOXO3a on hPASMCs in vitro.

Materials And Methods

Animals and experimental design

Healthy 6 to 8 week old female Sprague-Dawley rats (170-190 g) were purchased from the animal center of the Hebei Medical University, China. All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Hebei Medical University and complied with the Declaration of the National Institutes of Health Guide for Care and Use of Laboratory Animals.

The rats underwent bilateral ovariectomy and were randomized into four groups (n = 8/group): normoxia group, normoxia+E2 group, hypoxia group, and hypoxia+E2 group. Previous studies showed that hypoxia exposure for 2-4 weeks can establish HPH models (21, 22). One week after surgery, the animals received 17β-estradiol (20 μg/kg/d, Sigma, St Louis, MO, USA) or saline (0.1 ml/d) subcutaneously for 8 weeks, as described (23). An additional file shows this in more detail (see Additional file 1).

Hemodynamics, hormone assays, and tissue preparation

Hemodynamics were recorded using a Med lab electrophysiolograph (BL-420S, Thaimeng Technology Co., Ltd., Chengdu, China). A commercially available estradiol ELISA kit (DRG International Inc.,
Springeld Township, NJ, USA) was used to detect the hormone levels. The lungs and heart were harvested. An additional file shows this in more detail (see Additional file 1).

**Pathology and immunochemical staining**

Immunohistochemistry was routinely performed for SIRT1 (1:400; ab110304, Abcam, Cambridge, MA, USA), FOXO3a (1:400; ab109629, Abcam, Cambridge, MA, USA), and PCNA (1:400; 610664, BD Biosciences, Franklin Lake, NJ, USA). An additional file shows this in more detail (see Additional file 1).

**Cell culture and treatment**

HPASMCs (3110, Sciencell Research Laboratories, Carlsbad, CA, USA) were routinely cultured at 37°C in smooth muscle cell medium (Sciencell Research Laboratories, Carlsbad, CA, USA) supplemented with 2% fetal bovine serum (Sciencell Research Laboratories, Carlsbad, CA, USA), 0.5% smooth muscle cell growth supplement (Sciencell Research Laboratories, Carlsbad, CA, USA), and 0.5% penicillin-streptomycin solution (Sciencell Research Laboratories, Carlsbad, CA, USA). The cells were divided into six groups: one normoxia group, four hypoxia groups treated with four different concentrations of E2 (10⁻⁶, 10⁻⁷, 10⁻⁸, and 10⁻⁹ mol/L), and one hypoxia alone group. An additional file shows this in more detail (see Additional file 1).

**Cell proliferation assay**

HPASMC proliferation was determined routinely using the MTT assay (MTT; D0801, Sigma, St Louis, MO, USA). An additional file shows this in more detail (see Additional file 1).

**Western blotting**

Western blotting was performed routinely for SIRT1 (ab110304, Abcam, Cambridge, MA, USA), FOXO3a (ab109629, Abcam, Cambridge, MA, USA), PCNA (610664, BD Biosciences, Franklin Lake, NJ, USA), and GAPDH (Abcam, Cambridge, MA, USA). An additional file shows this in more detail (see Additional file 1).

**RT-PCR analysis**

RT-PCR was performed routinely for SIRT1, FOXO3a, and GAPDH (172 bp). The expression levels of the target genes were calculated using the \(2^{-\Delta \Delta Ct}\) method (24). An additional file shows this in more detail (see Additional file 1).

**SIRT1 deacetylase activity assay**
SIRT1 deacetylase activity was assayed using the Universal SIRT Activity Assay Kit (Abcam, Cambridge, MA, USA), according to the manufacturer’s instructions.

**Statistical analysis**

All data were expressed as means ± standard deviation (SD). Statistical analysis was performed using one-way ANOVA, followed by the least significant difference (LSD) test for post hoc multiple comparisons. Significant difference was accepted at P<0.05. Analyses were performed using SPSS 21.0 (IBM, Armonk, NY, USA).

**Results**

**E2 attenuates chronic HPH and pulmonary artery remodeling in rats**

Compared with the normoxia group, the E2 levels in the normoxia+E2 group were significantly elevated. Compared with the hypoxia group, the E2 levels in the hypoxia+E2 group were significantly elevated (Figure 1A).

After 8 weeks of hypoxia, the mPAP of the hypoxia group was significantly elevated compared with the normoxia group (Figure 1B). In the hypoxia+E2 group, the mPAP was significantly lower than in the hypoxia group (Figure 1B), but it was still higher than in the normoxia group. There was no significant difference in mPAP between the normoxia and normoxia+E2 groups (Figure 1B).

As shown in Figure 2A, wall-thickened pulmonary arterioles with medial smooth muscle cell proliferation were observed in the hypoxia rats compared with those in the normoxia group. The vessel changes were alleviated in the hypoxia+E2 group compared with the hypoxia group (Figure 2A). Compared with the normoxia group, the MT% and RVHI in the hypoxia group were significantly elevated (Figures 1C and 2B). The rats treated with E2 showed relatively less severity of both indexes (Figures 1C and 2B). There was no significant difference of MT% and RVHI between the normoxia and normoxia+E2 groups (Figures 1C and 2B).

**E2 decreases hPASMCs proliferation under hypoxia**

Hypoxia significantly increased cell proliferation compared with the normoxia group (Figure 3). The hypoxia-induced proliferation of PASMCs was obviously inhibited by the four different concentrations of E2 (Figure 3). To determine whether SIRT1-FOXO3a mediates the effects of E2 on hPASMCs proliferation, the SIRT1 inhibitor nicotinamide (NAM) was used. Interestingly, hPASMCs cotreated with E2 and NAM exhibited significant attenuation of E2-induced improvements in hPASMCs proliferation under hypoxia (Figure 3B).
We next confirmed whether SIRT1 overexpression could duplicate the effects of E2 on hPASMCs proliferation \textit{in vitro}. Resveratrol (RE) was used as an activator of the SIRT1 protein. Cell proliferation of the RE-treated group was lower than in the hypoxia group (Figure 3B). HPASMCs proliferation was significantly reduced by 40 \( \mu \)M resveratrol.

**E2 increases the expression of SIRT1 in HPH rats**

To explore whether SIRT1 was involved in hypoxia-induced pulmonary hypertension and artery remodeling in rats, SIRT1 expression and deacetylase activity were detected. Immunohistochemistry showed that SIRT1 was highly expressed in pulmonary arterioles and image analysis showed that SIRT1 expression in the hypoxia group was decreased compared with the normoxia group (Figure 4A, D, E). Compared with the hypoxia group, SIRT1 expression in the E2 treatment group was significantly increased, but it was still lower than that of normoxia group (Figure 4A, D, E). There was no notable difference in SIRT1 expression between the normoxia and normoxia+E2 group (Figure 4A, D, E).

According to immunohistochemistry, compared with the normoxia group, hypoxia exposure significantly decreased the expression of the transcription factor FOXO3a (Figure 4B, D, E), accompanied with significant increase of PCNA expression (Figure 4C, D, E). Compared with the hypoxia group, FOXO3a expression in the E2 group was significantly increased (Figure 4B, D, E). PCNA expression in the E2 treatment group was significantly decreased (Figure 4C, D, E).

**SIRT1 activity in lung specimens**

There was no significant difference in SIRT1 activity among the groups (Figure 5).

**E2 increases the expression of SIRT1 in hPASMCs**

In line with the \textit{in vivo} findings, compared with the normoxia control, hypoxia significantly decreased the protein and mRNA expression SIRT1 in hPASMCs (Figure 6A, C). On the other hand, treatment with E2 (10\(^{-6}\) M) significantly increased the expression of SIRT1 (Figure 6A, C).

In accordance with the \textit{in vivo} findings, hypoxia resulted in reduction of FOXO3a in hPASMCs (Figure 6A, C) and elevation of PCNA (Figure 6B, D) compared with the normoxia group. In the hypoxia+E2 group, the protein and mRNA levels of FOXO3a were significantly increased (Figure 6A, C) and the protein and mRNA levels of PCNA were significantly reduced (Figure 6B, D) compared with the hypoxia group.

Compared with the E2 group, cotreatment with E2 and NAM decreased the expression of SIRT1 (Figure 6A, C) and repressed the expression of FOXO3a (Figure 6A, C), whereas the expression of PCNA was increased in this condition (Figure 6B, D).
We next confirmed whether SIRT1 overexpression could duplicate the effects of E2 on expression of FOXO3a and PCNA \textit{in vitro}. RE significantly increased the expression (Figure 6A, C) and increased the expression of FOXO3a (Figure 6A, C), but decreased the expression of PCNA in hypoxia-induced hPAMSCs (Figure 6B, D).

**Hypoxia reduces SIRT1 activity in hPASMCs, without effect of E2**

Not exactly consistent with the \textit{in vivo} findings, compared with the normoxia control, hypoxia significantly reduced SIRT1 activity (Figure 7). Whereas, treatment with E2 ($10^{-6}$ M) had no effect on SIRT1 activity (Figure 7). Compared with the normoxia group, cotreatment with E2 and NAM decreased the activity of SIRT1 (Figure 7). Compared with the hypoxia group, RE significantly increased the activity of SIRT1 (Figure 7).

**Discussion**

SIRT1 has anti-proliferation effects on cells through FOXO deacetylation and regulating the expression of FOXOs. E2 has protective effects against HPH, but the involvement of SIRT1 and FOXOs in the proliferation of PASMCs and their contribution to the effects of E2 on HPH are poorly understood. Therefore, this study aimed to use E2 to explore the roles of SIRT1 and FOXO3a in the pathogenesis and progression of HPH and PVR \textit{in vivo} and \textit{in vitro}. The results suggest that upregulation of SIRT1 and FOXO3a contributes to the protective role of estrogen on HPH in rats, as supported by \textit{in vitro} results using hPASMCs.

PH is a progressive and sexually dimorphic disease with high morbidity and mortality. HPH is a severe complication and important cause of death in patients with hypoxia-related lung diseases. HPH has a multi-factorial etiology that often leads to significant hemodynamic changes, severe pulmonary vascular remodeling, and right ventricular failure and death (25). Despite the development of novel therapies over the last 20 years, the clinical prognosis of PH is still poor.

Although females are much more susceptible than males to idiopathic, familial, and scleroderma-associated PH (26), there are discrepancies in mortality (27) and in the prevalence of HPH due to high altitude (28). In addition, female PH patients exhibit higher cardiac index and lower mPAP and PVR (29), and better RV function (30). Under hypoxia, animal models (rats, chicken, sheep, and swine) develop less severe PH than their male counterparts (31–34). Previous studies by our group and others’ showed that hypoxic ovariectomized rats develop more severe PH, PVR, and RV hypertrophy than chronically hypoxic rats with intact ovaries (4, 5, 9). Furthermore, administration of estrogen attenuates the severity of PH in the ovariectomized animals (4, 5, 9). Along these lines, estrogen may influence the development of hypoxia-induced PH. In the present study, hypoxia induced pathologic changes that were typical of HPH, such as elevated mPAP, increased RV/LV+S and MT%. In addition, E2 alleviated these changes.
PVR plays a critical role in the progression of HPH in animal models as well as in patients with HPH, and abnormal proliferation of PASMCs leads to media hyperplasia and vessel lumen stenosis, resulting in increased pulmonary vascular resistance and elevated mPAP (3). Although many studies on estrogen revealed that it could effectively alleviate various types of vascular diseases, there are still many controversies over the beneficial effects of estrogen, especially over its anti-proliferation effect (10, 26, 35). To date, the effects of estrogen on PVR are still not clear. In the present study, we found that E2 significantly attenuated hypoxia-induced pulmonary artery remodeling in vivo and inhibited hPASMCs proliferation under hypoxia in vitro. The results are consistent with those reported by Xu et al. (10). In our opinion, the controversies about estrogen's anti-proliferation effect may due to different animal models, different target cells, different experimental conditions, and different treatments. Nevertheless, the molecular mechanisms responsible for the anti-proliferation effect are complex and have not yet been fully elucidated.

SIRT1, as an important class III histone deacetylase, participates in many cell functions such as proliferation, differentiation, senescence, and apoptosis (36–39). SIRT1 plays critical roles in vascular homeostasis and remodeling (39, 40). Bae et al. (41) demonstrated that SIRT1 attenuates neointima formation by inhibiting HIF-1α expression in neointimal lesions of a murine model of wire-injured femoral artery. Gao et al. (42) reported that SIRT1 expression is decreased in the aortas of angiotensin II infusion-induced hypertension mouse models. Overexpression of SIRT1 in VSMCs prevents the increase in systolic blood pressure caused by AngII infusion and alleviates vascular remodeling in thoracic and renal aortas. With respect to VSMC proliferation and arterial remodeling within the pulmonary vasculature, studies also showed that decreased SIRT1 expression may contribute to PVR in monocrotaline (MCT)-induced PH models, and up-regulated SIRT1 revealed the inhibition effect on MCT-induced rat PVR and PVSMCs proliferation by modulating different molecules (14, 43).

In this study, data showed that hypoxia decreased the expression of SIRT1 along with increase of PCNA expression. E2 reversed these changes of SIRT1 and PCNA, accompanied with the attenuation of PH and PVR induced by hypoxia. Interestingly, there was a positive association between SIRT1 and FOXO3a. Moreover, similar phenomena were also observed at the cellular level. SIRT1 activity was not changed after E2 treatment both in vitro and in vivo, but it was reduced after hypoxia in cultured hPASMCs. These results suggest that the protective effects of E2 on the HPH and hPASMCs proliferation were related to the improvement of SIRT1 expression levels and elevation of FOXO3a expression levels.

FOXO transcription factors play critical roles in cell proliferation, apoptosis, and cell cycle arrest and are becoming the focus of research in a variety of vascular diseases and cancers (15, 16, 44). As an important isoform of the FOXO family, FOXO3a has proved to be an important regulator that modulates vascular homeostasis, VSMC proliferation, and neointimal hyperplasia (45). In addition, FOXO3a is regulated by SIRT1 (46). Huang et al. (47) revealed that physiological cyclic stretch increased SIRT1 expression, which subsequently up-regulated the expression of FOXO3a and maintained the normal contractile differentiation of VSMCs. In contrast, Zhang et al. (48) showed that in MSCs, inhibition of miR-34a led to an increase in SIRT1 expression, which down-regulated the protein expression of FOXO3a,
resulting in decreased cell apoptosis and increased survival. In the present study, there was a positive association between SIRT1 and FOXO3a expression. Further studies in cultured hPASMCs showed that cells cotreated with E2 and NAM exhibited significant reduction of expression and activity of SIRT1 and marked attenuation of E2-induced improvements in hPASMCs proliferation and FOXO3a expression under hypoxia. Resveratrol (RE), an activator of the SIRT1 protein, mimicked the effects of E2 on hPASMCs proliferation and expression of FOXO3a. These results revealed that E2 increased the expression of SIRT1, which subsequently modulated the expression of FOXO3a and then the proliferation of PASMCs. The expression of FOXOs are regulated by SIRT1 in several types of cells (49, 50). Recent research revealed that the host cell factor 1 (HCF-1) participates in the SIRT1-regulated expression of FOXOs in worms (38). In addition, there is also evidence that SIRT1 deacetylates FOXOs, thus attenuating cell apoptosis and cell-cycle arrest (46). Accordingly, we could not exclude that SIRT1-mediated deacetylation of FOXO3a or other molecules may also contribute to the anti-remodeling effect of E2 and further investigation is needed.

Conclusions

In conclusion, the present study strongly suggests that E2 upregulates the expression of SIRT1 and consequently increases the expression of FOXO3a in hypoxia-induced hPASMCs, which contributed to the attenuation of pulmonary arterial remodeling and the alleviation of PH in hypoxia-treated rats. It suggests that E2 exerts a protective role in HPH, at least in part through the regulation of the SIRT1-FOXO3a signaling axis in vascular smooth muscle cells.

Abbreviations

HPH: hypoxic pulmonary hypertension

NAM: nicotinamide

PH: pulmonary hypertension

RE: resveratrol

PASMCs: pulmonary artery smooth muscle cells

mPAP: mean pulmonary arterial pressure

E2: estrogen

MT: medial wall thickness

SIRT1: silent mating type information regulation 2 homolog-1

PCNA: proliferated cell nuclear antigen
Declarations

Ethics approval and consent to participate

All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Hebei Medical University and complied with the Declaration of the National Institutes of Health Guide for Care and Use of Laboratory Animals.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the Key Science and Technology Research Planning of department of health of Hebei Province of China (2016027).

Authors' contributions

LW conceived and designed the experiments, performed experiments and drafted the manuscript. YY contributed to conception and critically revised the manuscript. XG and JM performed experiments and participated in analysis. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References
1. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493–537.

2. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res. 2006;99(7):675–91.

3. Ricard N, Tu L, Le Hiress M, Huertas A, Phan C, Thuillet R, et al. Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension. Circulation. 2014;129(15):1586–97.

4. Yuan M, Duan Z, Sun Y, Yuan Y. [Effects of estrogen on ACE-Ang II-AT1 axis in ovariectomy and hypoxic pulmonary hypertension rats]. Zhonghua yi xue za zhi. 2014;94(22):1696–700.

5. Resta TC, Kanagy NL, Walker BR. Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. Am J Physiol Lung Cell Mol Physiol. 2001;280(1):L88–97.

6. Sherman TS, Chambliss KL, Gibson LL, Pace MC, Mendelsohn ME, Pfister SL, et al. Estrogen acutely activates prostacyclin synthesis in ovine fetal pulmonary artery endothelium. Am J Respir Cell Mol Biol. 2002;26(5):610–6.

7. Lahm T, Crisostomo PR, Markel TA, Wang M, Wang Y, Tan J, et al. Selective estrogen receptor-alpha and estrogen receptor-beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism. Am J Physiol Regul Integr Comp Physiol. 2008;295(5):R1486-93.

8. Earley S, Resta TC. Estradiol attenuates hypoxia-induced pulmonary endothelin-1 gene expression. Am J Physiol Lung Cell Mol Physiol. 2002;283(1):L86–93.

9. Zheng Q, Yuan YD, Zhao J. [Effect of Estradiol and its Metabolite on Hypoxic Induced Factor-1α and Alkane Hydroxylase in Experimental Rats With Ovariectomy and Hypoxic Pulmonary Hypertension]. Chin Circ J. 2015;30(9):884–8.

10. Xu D, Niu W, Luo Y, Zhang B, Liu M, Dong H, et al. Endogenous estrogen attenuates hypoxia-induced pulmonary hypertension by inhibiting pulmonary arterial vasoconstriction and pulmonary arterial smooth muscle cells proliferation. Int J Med Sci. 2013;10(6):771–81.

11. Tarhouni K, Freidja ML, Guihot AL, Vessieres E, Grimaud L, Toutain B, et al. Role of estrogens and age in flow-mediated outward remodeling of rat mesenteric resistance arteries. Am J Physiol Heart Circ Physiol. 2014;307(4):H504-14.

12. Feige JN, Auwerx J. Transcriptional targets of sirtuins in the coordination of mammalian physiology. Curr Opin Cell Biol. 2008;20(3):303–9.

13. Yu L, Tu Y, Jia X, Fang K, Liu L, Wan L, et al. Resveratrol Protects Against Pulmonary Arterial Hypertension in Rats via Activation of Silent Information Regulator 1. Cell Physiol Biochem. 2017;42(1):55–67.

14. Zhou S, Li MT, Jia YY, Liu JJ, Wang Q, Tian Z, et al. Regulation of Cell Cycle Regulators by SIRT1 Contributes to Resveratrol-Mediated Prevention of Pulmonary Arterial Hypertension. Biomed Res Int.
15. Tang YL, Huang LB, Lin WH, Wang LN, Tian Y, Shi D, et al. Butein inhibits cell proliferation and induces cell cycle arrest in acute lymphoblastic leukemia via FOXO3a/p27kip1 pathway. Oncotarget. 2016;7(14):18651–64.

16. Sunayama J, Sato A, Matsuda K, Tachibana K, Watanabe E, Seino S, et al. FOXO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity. Stem Cells. 2011;29(9):1327–37.

17. Zhang S, Zhao Y, Xu M, Yu L, Zhao Y, Chen J, et al. FoxO3a modulates hypoxia stress induced oxidative stress and apoptosis in cardiac microvascular endothelial cells. PLoS One. 2013;8(11):e80342.

18. Pullamsetti SS, Perros F, Chelladurai P, Yuan J, Stenmark K. Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series). Pulm Circ. 2016;6(4):448–64.

19. Ferguson D, Shao N, Heller E, Feng J, Neve R, Kim HD, et al. SIRT1-FOXO3a regulate cocaine actions in the nucleus accumbens. J Neurosci. 2015;35(7):3100–11.

20. Hori YS, Kuno A, Hosoda R, Horio Y. Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS One. 2013;8(9):e73875.

21. Yu SH, Chen JY, Zhang YM, Jiao GW, Liu FQ, Kong LF. Effect of thoracic epidural blockade on hypoxia-induced pulmonary arterial hypertension in rats. Iran J Basic Med Sci. 2014;17(9):710–5.

22. Yu L, Hales CA. Effect of chemokine receptor CXCR4 on hypoxia-induced pulmonary hypertension and vascular remodeling in rats. Respir Res. 2011;12:21.

23. Wang L, Zheng Q, Yuan Y, Li Y, Gong X. Effects of 17β-estradiol and 2-methoxyestradiol on the oxidative stress-hypoxia inducible factor-1 pathway in hypoxic pulmonary hypertensive rats. Exp Ther Med. 2017;13(5):2537–43.

24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.

25. Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019;53(1).

26. Lahm T, Tuder RM, Petrache I. Progress in solving the sex hormone paradox in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2014;307(1):L7–26.

27. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156–63.

28. Ge RL, Helun G. Current concept of chronic mountain sickness: pulmonary hypertension-related high-altitude heart disease. Wilderness Environ Med. 2001;12(3):190–4.
29. Ventetuolo CE, Praestgaard A, Palevsky HI, Klinger JR, Halpern SD, Kawut SM. Sex and haemodynamics in pulmonary arterial hypertension. Eur Respir J. 2014;43(2):523–30.
30. Kawut SM, Al-Naamani N, Agerstrand C, Berman Rosenzweig E, Rowan C, Barst RJ, et al. Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest. 2009;135(3):752–9.
31. Rabinovitch M, Gamble WJ, Miettinen OS, Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol. 1981;240(1):H62–72.
32. Wetzel RC, Sylvester JT. Gender differences in hypoxic vascular response of isolated sheep lungs. J Appl Physiol Respir Environ Exerc Physiol. 1983;55(1 Pt 1):100–4.
33. Burton RR, Besch EL, Smith AH. Effect of chronic hypoxia on the pulmonary arterial blood pressure of the chicken. Am J Physiol. 1968;214(6):1438–42.
34. McMurtry IF, Frith CH, Will DH. Cardiopulmonary responses of male and female swine to simulated high altitude. J Appl Physiol. 1973;35(4):459–62.
35. Mair KM, Yang XD, Long L, White K, Wallace E, Ewart MA, et al. Sex affects bone morphogenetic protein type II receptor signaling in pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2015;191(6):693–703.
36. Han Y, Fukuda N, Ueno T, Endo M, Ikeda K, Xueli Z, et al. Role of complement 3a in the synthetic phenotype and angiotensin II-production in vascular smooth muscle cells from spontaneously hypertensive rats. Am J Hypertens. 2012;25(3):284–9.
37. Simic P, Zainabadi K, Bell E, Sykes DB, Saez B, Lotinun S, et al. SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating beta-catenin. EMBO Mol Med. 2013;5(3):430–40.
38. Xiong S, Salazar G, Patrushev N, Ma M, Forouzandeh F, Hilenski L, et al. Peroxisome proliferator-activated receptor gamma coactivator-1alpha is a central negative regulator of vascular senescence. Arterioscler Thromb Vasc Biol. 2013;33(3):988–98.
39. Yao QP, Qi YX, Zhang P, Cheng BB, Yan ZQ, Jiang ZL. SIRT1 and Connexin40 Mediate the normal shear stress-induced inhibition of the proliferation of endothelial cells co-cultured with vascular smooth muscle cells. Cell Physiol Biochem. 2013;31(2–3):389–99.
40. Cheng BB, Yan ZQ, Yao QP, Shen BR, Wang JY, Gao LZ, et al. Association of SIRT1 expression with shear stress induced endothelial progenitor cell differentiation. J Cell Biochem. 2012;113(12):3663–71.
41. Bae JU, Lee SJ, Seo KW, Kim YH, Park SY, Bae SS, et al. SIRT1 attenuates neointima formation by inhibiting HIF-1alpha expression in neointimal lesion of a murine wire-injured femoral artery. Int J Cardiol. 2013;168(4):4393–6.
42. Gao P, Xu TT, Lu J, Li L, Xu J, Hao DL, et al. Overexpression of SIRT1 in vascular smooth muscle cells attenuates angiotensin II-induced vascular remodeling and hypertension in mice. J Mol Med (Berl). 2014;92(4):347–57.
43. Paffett ML, Lucas SN, Campen MJ. Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle. Vascul Pharmacol.
44. Oellerich MF, Potente M. FOXOs and sirtuins in vascular growth, maintenance, and aging. Circ Res. 2012;110(9):1238–51.

45. Lee HY, Chung JW, Youn SW, Kim JY, Park KW, Koo BK, et al. Forkhead transcription factor FOXO3a is a negative regulator of angiogenic immediate early gene CYR61, leading to inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res. 2007;100(3):372–80.

46. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303(5666):2011–5.

47. Huang K, Yan ZQ, Zhao D, Chen SG, Gao LZ, Zhang P, et al. SIRT1 and FOXO Mediate Contractile Differentiation of Vascular Smooth Muscle Cells under Cyclic Stretch. Cell Physiol Biochem. 2015;37(5):1817–29.

48. Zhang F, Cui J, Liu X, Lv B, Liu X, Xie Z, et al. Roles of microRNA-34a targeting SIRT1 in mesenchymal stem cells. Stem Cell Res Ther. 2015;6:195.

49. Hsu CP, Zhai P, Yamamoto T, Maejima Y, Matsushima S, Hariharan N, et al. Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation. 2010;122(21):2170–82.

50. Rizki G, Iwata TN, Li J, Riedel CG, Picard CL, Jan M, et al. The evolutionarily conserved longevity determinants HCF-1 and SIR-2.1/SIRT1 collaborate to regulate DAF-16/FOXO. PLoS Genet. 2011;7(9):e1002235.

51. Additional file 1.

52. DOC.

53. Supplemental. materials and methods.

**Figures**

![Figure A](image1.png)

![Figure B](image2.png)

![Figure C](image3.png)
Figure 1

Effects of E2 on chronic hypoxia-induced pulmonary hypertension and right ventricular hypertrophy of rats. (A) 17β-estradiol levels in serum. (B) Mean pulmonary artery pressure (mPAP). (C) Right ventricular hypertrophy, showing data as the mass of the right ventricle divided by the masses of the left ventricles and septum [RV/(LV+S)]. **P<0.01,*P<0.05 vs. the normoxia group. ##P<0.01, #P<0.05 vs. the hypoxia group.

Figure 2

Effects of E2 on chronic hypoxia-induced pulmonary vascular remodeling of rats. (A) Hematoxylin and eosin staining of pulmonary arterioles (magnification of 20× and scale bars of 50 μm). (B) Medial wall thickness (MT%) of pulmonary arterioles. **P<0.01 vs. the normoxia group. ##P<0.01 vs. the hypoxia group.
Figure 3

Effects of E2 (A) and SIRT1 activator/inhibitor (B) on hPASMCs proliferation under hypoxia (MTT assay).

**P<0.01, *P<0.05 vs. the normoxia group. ##P<0.01, #P<0.05 vs. the hypoxia group.
Figure 4

Effects of E2 on SIRT1, FOXO3a, and PCNA expression in rats. (A) Immunohistochemistry of SIRT1. (B) Immunohistochemistry of FOXO3a. (C) Immunohistochemistry of PCNA. (D) Densitometry analysis of the immunohistochemistry images. (E) Positive cell percentage based on the immunohistochemistry images. Magnification of 40× and scale bars of 25 μm. **P<0.01, *P<0.05 vs. the normoxia group. ##P<0.01, #P<0.05 vs. the hypoxia group.
Figure 5

Effects of E2 on SIRT1 activity in rats. Quantitative analysis of SIRT1 activity in lung specimens.
Figure 6

Effects of E2 and SIRT1 activator/inhibitor on SIRT1, FOXO3a, and PCNA expression in hPASMCs. (A) Representative western blotting analysis of SIRT1 and FOXO3a protein levels in hPASMCs. (B) Representative western blotting analysis of PCNA protein levels in hPASMCs. (C) Representative RT-PCR analysis of SIRT1 and FOXO3a mRNA levels in hPASMCs. (D) Representative RT-PCR analysis of PCNA mRNA levels in hPASMCs. **P<0.01 vs. the normoxia group. ##P<0.01, #P<0.05 vs. the hypoxia group. &&P<0.01 vs. the hypoxia+E2 group.
Figure 7

Effects of E2 and SIRT1 activator/inhibitor on SIRT1 activity in hPASMCs. Quantitative analysis of SIRT1 activity in hPASMCs. **P<0.01, *P<0.05 vs. the normoxia group. ##P<0.01 vs. the hypoxia group.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.doc